Marshall Wace North America’s Acumen Pharmaceuticals ABOS Stock Holding History

Marshall Wace North America’s Portfolio ABOS Stock Details ABOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	$2.29M	Buy	+153,908	New	+$2.56M	0.01%	695

Other funds holding ABOS

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $614M AUM 19.92% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

LCM

Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return

GPC

Guardian Point Capital Charlottesville, Virginia $325M AUM 40.6% 1-Year Est. Return

Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Marshall Wace North America's ABOS Position: Q3 2021 in Review

Marshall Wace North America opened a new position in Acumen Pharmaceuticals (ABOS) in Q3 2021: 153,908 shares worth $2.29M. The stake represents 0.01% of the portfolio and ranks #695 among its holdings.

41 funds tracked by Wall St. Rank hold ABOS as of Q3 2021.

Marshall Wace North America held 153,908 shares of Acumen Pharmaceuticals worth $2.29M as of Q3 2021.
Acumen Pharmaceuticals was a new Marshall Wace North America position in Q3 2021.
Acumen Pharmaceuticals made up 0.01% of Marshall Wace North America's portfolio in Q3 2021, its #695 holding.
41 funds tracked by Wall St. Rank held Acumen Pharmaceuticals as of Q3 2021.

Based on Marshall Wace North America's 13F filing for Q3 2021, filed 15 Nov 2021.